Lin Jordan

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

E. N. Dolzhenko

Fedorovsky Polar State University

Rosa Pritchard

Beaumont Hospital, Dearborn

Laura Young

Milken Institute

Jamie Hyatt

Group for the Analysis of Development

John B. Buse

University of North Carolina at Chapel Hill

Paige Miller

Texas Department of State Health Services

Jamie Diner

University of Colorado Anschutz Medical Campus

Peter Calhoun

Jaeb Center for Health Research

Klara R. Klein

University of North Carolina at Chapel Hill

Roy W. Beck

Jaeb Center for Health Research

Cooperative Institutions

University of Colorado Anschutz Medical Campus

Jaeb Center for Health Research

Boston University

Massachusetts General Hospital

The University of Texas Southwestern Medical Center

Children's Hospital of Orange County

The University of Texas Health Science Center at San Antonio

University of Colorado Denver

Harvard University

University of North Carolina at Chapel Hill

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

The Insulin-Only Bionic Pancreas Improves Glycemic Control in Non-Hispanic White and Minority Adults and Children With Type 1 Diabetes

Diabetes Care (2023)

Luz E. Castellanos Steven Russell Edward R. Damiano Roy W. Beck Viral N. Shah

OBJECTIVE We evaluated the performance of the iLet bionic pancreas (BP) in non-Hispanic White individuals (here referred to as “Whites”) and in Black, Hispanic, and other individuals (here collectively referred to as “Minorities”). RESEARCH DESIGN AND METHODS A multicenter, randomized controlled trial evaluated glycemic management with the BP versus standard of care (SC) in 161 adult and 165 pediatric participants with type 1 diabetes over 13 weeks. RESULTS In Whites (n = 240), the mean baseline-adjusted difference in 13-week HbA1c between the BP and SC groups was −0.45% (95% CI −0.61 to −0.29 [−4.9 mmol/mol; −6.6 to −3.1]; P < 0.001), while this difference among Minorities (n = 84) was −0.53% (−0.83 to −0.24 [−6.0 mmol/mol; −9.2 to −2.8]; P < 0.001). In Whites, the mean baseline-adjusted difference in time in range between the BP and SC groups was 10% (95% CI 7–12; P < 0.001) and in Minorities was 14% (10–18; P < 0.001). CONCLUSIONS The BP improves glycemic control in both Whites and Minorities and offers promise in decreasing health care disparities.

10.2337/dc22-1478

Cite

Citations (5)

A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery

Diabetes Care (2024)

Irl B. Hirsch Roy W. Beck Martin Chase Marak Peter Calhoun Adham Mottalib

To compare postprandial glucose excursions following a bolus with inhaled technosphere insulin (TI) or subcutaneous rapid-acting analog (RAA) insulin.

Bolus (digestion)

Insulin analog

10.2337/dc24-0838

Cite

Citations (1)

A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes

Diabetes Care (2024)

Irl B. Hirsch Roy W. Beck Martin Chase Marak Yogish C. Kudva Halis Kaan Aktürk

OBJECTIVE To evaluate a regimen of inhaled Technosphere insulin (TI) plus insulin degludec in adults with type 1 diabetes, who prestudy were predominately using either an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) with continuous glucose monitoring. RESEARCH DESIGN AND METHODS At 19 sites, adults with type 1 diabetes were randomly assigned to TI plus insulin degludec (N = 62) or usual care (UC) with continuation of prestudy insulin delivery method (N = 61) for 17 weeks. RESULTS Prestudy, AID was used by 48% and MDI by 45%. Mean ± SD HbA1c was 7.57% ± 0.97% at baseline and 7.62% ± 1.06% at 17 weeks in the TI group and 7.59% ± 0.80% and 7.54% ± 0.77%, respectively, in the UC group (adjusted difference 0.11%, 95% CI −0.10 to 0.33, P value for noninferiority = 0.01). HbA1c improved from baseline to 17 weeks by >0.5% (5.5 mmol/mol) in 12 (21%) in the TI group and in 3 (5%) in the UC group and worsened by >0.5% (5.5 mmol/mol) in 15 (26%) in the TI group and in 2 (3%) in the UC group. The most common TI side effect was a brief cough; eight participants discontinued TI due to side effects. CONCLUSIONS In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.

Regimen

Insulin degludec

Basal (medicine)

10.2337/dc24-1832

Cite

Citations (1)